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OBJECTIVE: Aims: To estimate the cost effectiveness of treat-
ment with peginterferon alfa-2b plus ribavirin compared with
interferon alfa-2b plus ribavirin for initial treatment of patients
with chronic hepatitis C. METHODS: Individual patient level
data from a randomised clinical trial with peginterferon plus rib-
avirin were applied to a Markov model to project lifelong clini-
cal outcomes. Economic estimates and quality of life were based
on Taiwan patient data and published data. We used a societal
perspective and applied a 3% annual discount rate. RESULTS:
Compared with no antiviral therapy, interferon alfa-2b plus
weight based dosing of ribavirin or peginterferon alfa-2b plus
weight based dosing of ribavirin 24 weeks therapy increased
quality adjusted life year (QALY) on overall hepatitis C patients
by 6.5 and 6.7 years, respectively. And the life long treatment
costs are lower than no antiviral therapy. The peginterferon plus
weight based dosing of ribavirin therapy on genotype I patients
is dominate. On the other hand, use interferon plus weight based
dosing of ribavirin to treat non-genotype I Chinese patients is
the most cost-effectiveness therapy. If the SVR of interferon plus
weight based dosing of ribavirin is below 67.8%, the best strat-
egy of treating non-genotype I Chinese patients will be The
peginterferon plus weight based dosing of ribavirin. CONCLU-
SIONS: Peginterferon alfa-2b plus ribavirin should reduce the
incidence of liver complications, prolong life, improve quality of
life, and be cost effective for the initial treatment of Chinese
chronic hepatitis C.
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OBJECTIVE: To assess the Annual Cost of Illness (CoI) of
GERD in an employed population. METHODS: A retrospective
analysis was conducted using the Human Capital Management
Services Research Reference database of multiple large geo-
graphically diverse US based employees with data from 2001
through 2004. Data included medical, pharmacy, payroll and
demographic data. The analysis compared the direct medical
costs by Place of Service (PoS: doctor’s ofﬁce, inpatient hospital,
outpatient hospital or clinic, emergency department, laboratory,
other) for a subset of employees where this data was available.
ICD-9 Codes were used to distinguish employees with GERD
from the non-GERD cohort. The index date in the GERD cohort
was deﬁned as the date of ﬁrst diagnosis during 2001 or later,
while the average GERD index date was used in the non-GERD
cohort. Regression modelling was used to measure the cost dif-
ferences between employees with GERD and employees without
GERD while controlling for age, job tenure, gender, salary,
region, and comorbidities. RESULTS: Data were available 
for 267,269 employees (4.3% with GERD). The mean age of
employees with GERD was 43 years, and 94% were full time
employees. All of the annual CoI and PoS comparisons were sta-
tistically different (all P < 0.001). GERD was associated with an
annual mean incremental cost of $3,355, of which direct medical
costs accounted for 65%, prescription drug costs for 17%, and
indirect costs in terms of sick leave, short- and long-term dis-
ability, and workers’ compensation for 19%. The largest PoS
component (47%) was in the category “outpatient hospital or
clinic”. CONCLUSIONS: GERD is associated with substantial
direct and indirect costs, of which direct medical costs exclud-
ing prescription medications contributed to 65% of total incre-
mental costs in this study.
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OBJECTIVES: The objective of this study is to analyze the eco-
nomic burden of exogenous endoscopy-related infections,
pseudo-infections and toxic reactions in the U.S. in 2004.
METHODS: The economic burden was estimated from the U.S.
health care perspective. The number of events and patients
involved was estimated based on a review of the literature. An
analysis of the causes of contamination was conducted to eval-
uate preventable events. The use of resources was estimated for
patients exposed, contaminated and experiencing clinical symp-
toms. The use of resources included chart reviews, physician
visits, clinical tests, and interventions required for the treatment
of the infections and toxic reactions. The valuation of resources
was based on a review of the literature. A sensitivity analysis of
the incidence of endoscopy-related events and the use and valu-
ation of resources was conducted. RESULTS: The analysis
yielded a baseline incidence of 2741 patients exposed to
endoscopy-related events; 208 patients contaminated; and 113
patients experiencing clinical symptoms. It was estimated that
91.7% of the cases could be prevented if better infection control
practices were implemented, and that 93.3% of the cases could
be prevented if protective endoscope sheaths were used during
procedures. The total direct medical cost associated with
endoscopy-related infections occurring in the US in 2004 was
estimated at $7.6 million (range = $2.8–$14.7 million). Health
care expenditures for patients experiencing clinical symptoms
and evaluation of patient exposed represented 61.3% and 34.8%
of the total cost respectively. CONCLUSIONS: The analysis of
the economic burden associated with endoscopy-related events
reveals the signiﬁcance of the costs related to the care of patients
experiencing clinical symptoms, and the review of patients’
medical charts and the clinical evaluation of exposed patients.
The use of protective endoscope sheaths during procedures,
improved infection control, and surveillance systems could
reduce the economic burden associated with endoscopy-related
events.
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COST-UTILITY ANALYSIS OF TEGASEROD FOR THE
TREATMENT OF IRRITABLE BOWEL SYNDROME
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OBJECTIVES: Tegaserod appears to be safe and effective for
treating constipation-predominant irritable bowel syndrome
(IBS-C). The present study evaluates whether tegaserod is cost-
effective compared to usual care, which consists of education,
reassurance, suggestions on lifestyle and diet, and discussion
about psychosocial issues. METHODS: The study employed a
Markov-cycle tree to evaluate the medical and economic out-
